Active trials are investigating JX-594 in combination with cemiplimab for metastatic RCC (NCT03294083), anti-PD-L1 antibodies for melanoma (NCT04849260), and as neoadjuvant monotherapy for prostate cancer (EudraCT 2012–000704-15). This evidence concerns the gene CD274 and prostate cancer.